A decade of physiology, now in patients.
Ceryx’s therapy rests on peer-reviewed research showing that restoring heart–lung synchronisation improves a failing heart, and on RSA-Pace, the first randomised study of the approach in people.
RSA-Pace
RSA-Pace is a multicentre, randomised study of heart–lung synchronisation pacing in patients with heart failure, delivered via a temporary external pacing system. Patients were randomised to synchronised pacing or conventional pacing in the days after cardiac surgery, when temporary pacing wires are already in place.
The study is the first time heart–lung synchronisation pacing has been tested in people with heart failure. Enrolment completed in 2026 and the full analysis, including continuous ECG recordings from every patient, is now under way with independent electrophysiologists.
Results will be published once the analysis is complete.
- Design
- Randomised, open-label, parallel-group
- Patients
- 32 randomised
- Sites
- 5 hospitals
- Countries
- UK, Australia, New Zealand
- Participating centres
- University Hospital of Wales, Cardiff · Bristol Heart Institute · Waikato Hospital, New Zealand · Royal Adelaide Hospital · Victorian Heart Hospital, Melbourne
- Registration
- ClinicalTrials.gov NCT06359938 · Sponsor: Ceryx Medical Ltd
From external system to implant
Ceryx has moved deliberately: prove the therapy with an external system first, then build the implant. The company has already manufactured its first implantable device and is developing the Cysoni implantable pulse generator with ISO 13485 engineering partners.
Therapy validation
Preclinical studies in heart failure models; RSA-Pace clinical study enrolled and closed.
Cysoni implant development
Implantable pulse generator design with ISO 13485 partners; first implantable device built at MAISI, King’s College London.
Regulatory strategy
FDA pathway and Breakthrough Device Designation strategy in preparation with specialist regulatory advisers.
First implant study
Pilot clinical study of the implantable Cysoni system.
Want the detail?
Qualified investors and prospective partners can request the clinical data pack under NDA.